Bangkok, Thailand — 2024
In a major leap forward for Thailand’s regenerative medicine capabilities, Villa Medical Center Phuket (www.thailandstemcell.com) has entered into a strategic collaboration with the Thailand Institute of Scientific and Technological Research (TISTR) (www.tistr.or.th) to establish a state-of-the-art Mesenchymal Stem Cell (MSC) infrastructure. This public-private partnership is designed to enhance the country’s clinical readiness in stem cell therapy, accelerate translational research, and support Thailand’s long-term goal of becoming a hub for ATMP (Advanced Therapy Medicinal Products) innovation in Southeast Asia.
Villa Medical Center Phuket is a wholly owned subsidiary of Atlantis Bioscience Singapore (www.atlantisbioscience.com), a biotechnology company recognized across the Asia-Pacific region for its pioneering work in stem cell technologies, biologic reagent manufacturing, and ATMP formulation.
This collaboration with TISTR brings together the strengths of government-backed scientific research and private-sector regenerative medicine expertise. The joint mission is to establish standardized, scalable, and GMP-aligned processes for isolating, culturing, expanding, and characterizing MSCs derived from umbilical cord tissue and adipose sources.
Why Mesenchymal Stem Cells Matter for the Future of Medicine
Mesenchymal Stem Cells (MSCs) are multipotent progenitor cells with the ability to differentiate into bone, cartilage, fat, and other connective tissues. MSCs also possess powerful paracrine, immunomodulatory, and anti-inflammatory properties that make them ideal candidates for a wide range of clinical applications.
Globally, MSC-based therapies are at the forefront of treatments for:
- Osteoarthritis and joint degeneration
- Autoimmune diseases (e.g., lupus, Crohn’s)
- Neurological conditions (e.g., spinal cord injury, stroke)
- Organ fibrosis (e.g., liver, lung, kidney)
- Graft-versus-host disease (GVHD)
Thailand has a growing population of patients affected by chronic degenerative and inflammatory conditions. Setting up a reliable MSC manufacturing and research base not only addresses local healthcare needs but also boosts Thailand’s competitiveness in the global regenerative medicine market.
The Role of Villa Medical Center Phuket in the MSC Initiative
Villa Medical Center Phuket brings a robust operational framework to this partnership, with proven success in setting up stem cell therapy platforms, managing biological supply chains, and maintaining regulatory compliance in Thailand and across Southeast Asia.
As part of the collaboration with TISTR, Villa Medical Center Phuket is contributing:
- Custom-formulated MSC media optimized for high-yield, Xeno-free expansion
- GMP-relevant SOPs for MSC isolation, cryopreservation, and viability testing
- Training programs for Thai researchers, clinicians, and lab technicians
- Digital batch recordkeeping systems for quality traceability and clinical scalability
- Regulatory consultancy aligned with Thai FDA and ASEAN ATMP guidelines
This end-to-end technical and regulatory support ensures that the TISTR-Apollo MSC platform will meet international standards and enable downstream clinical use in hospitals and clinical trials.
TISTR’s Scientific Foundation and National Impact
Established in 1963, TISTR has long been a cornerstone of Thailand’s applied scientific research infrastructure. Its mission is to support national development through scientific innovation in agriculture, energy, health, and industrial biotechnology. TISTR’s capabilities in stem cell research, quality testing, and laboratory development have made it a natural partner in this high-impact collaboration.
By setting up an MSC platform in conjunction with Villa Medical Center Phuket, TISTR aims to:
- Strengthen domestic capability in stem cell processing and expansion
- Support hospitals with reliable, ready-to-use MSC batches for approved indications
- Provide a certified facility for preclinical and translational research projects
- Encourage the development of Thai-manufactured ATMPs
- Facilitate public education and awareness about the benefits and safety of stem cell therapy
This partnership exemplifies TISTR’s commitment to public health, national innovation, and global alignment in biomedical science.
Integration with Atlantis Bioscience Singapore: A Regional Blueprint
Behind this initiative is the scientific and operational ecosystem of Atlantis Bioscience Singapore, which has developed a wide-reaching network for the supply of stem cell technologies, exosome platforms, and ATMP-enabling reagents.
Atlantis Bioscience contributes:
- Decades of experience in stem cell therapy formulation
- Proven success in regional manufacturing (Thailand, Indonesia, Malaysia, China)
- Proprietary cell culture media and clinical research-grade supplements
- R&D leadership in cell-free biologics and extracellular vesicles
Through Villa Medical Center Phuket, the group can localize innovation, transfer technical know-how, and co-develop national centers of excellence, such as the one now emerging in Bangkok with TISTR.
Regulatory Readiness and GMP Alignment
One of the defining aspects of this collaboration is its focus on compliance with Thailand’s regulatory framework for cell and gene therapy products. Villa Medical Center Phuket has been instrumental in shaping SOPs and QC pipelines that adhere to:
- Thai FDA guidelines on stem cell processing and clinical use
- ASEAN ATMP harmonization policies
- WHO and PIC/S recommendations on cell therapy GMP conditions
Together with TISTR, Villa Medical Center Phuket is setting the stage for future submission of MSC products for clinical use, making this platform more than a research laboratory it is a springboard for patient-accessible therapy.
Capacity Building and Clinical Applications
The MSC platform is designed to be modular and scalable, supporting not only academic and translational research but also pilot-scale clinical batches for authorized stem cell therapy applications.
Target use cases include:
- Intra-articular MSC injections for osteoarthritis
- Intravenous MSC administration for autoimmune disease modulation
- Intrathecal MSC delivery for neuroinflammatory conditions
In parallel, Atlantis and TISTR are engaging with university hospitals, orthopedic specialists, and immunology clinics to initiate clinical studies and registry-based treatment programs under ethical review and governmental oversight.
Toward a National and Regional Center of Excellence
With the establishment of the MSC platform, Thailand takes a significant step toward becoming a regional Center of Excellence for stem cell therapy and ATMP research. The Atlantis–TISTR collaboration serves as a model for how public-private partnerships can elevate national capabilities, accelerate innovation, and enhance patient access to next-generation treatments.
Villa Medical Center Phuket envisions this initiative as the beginning of a broader movement toward collaborative research, knowledge transfer, and commercial readiness anchored in scientific rigor, safety, and ethical transparency.
Conclusion
By aligning its global experience with Thailand’s national vision, Villa Medical Center Phuket is proud to support TISTR in launching this foundational infrastructure for stem cell and regenerative therapy. With shared goals of improving patient outcomes, fostering scientific innovation, and driving economic development, the MSC platform represents a new chapter in Thailand’s leadership in stem cell therapy, MSC research, and ATMP advancement.
Villa Medical Center Phuket
Villa Sukhothai, Soi Pasak 8, Choeng Thale,
Thalang District, Phuket, Thailand
Email: atlantisphuket@gmail.com
Phone/WhatsApp: +66 99 301 6969